Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

Overview

Journal Glob Reg Health Technol Assess

Specialty Health Services

Date 2023 Jan 11

PMID 36627870

Authors

Stefano Fagiuoli

Matteo Ruggeri

Filipa Aragao

Rob Blissett

Affiliations

Soon will be listed here.

Abstract

Introduction: The current paradigm (CP) of hepatitis C virus (HCV) diagnosis and treatment in Italy's National Health Service system has numerous steps. The European Association for the Study of the Liver recommends initiation of a pan-genotypic direct-acting antiviral regimen after a simple diagnostic process. The present study estimated the efficiency gains resulting from two simplified pathways from diagnosis to treatment of chronic hepatitis C patients in Italy over the next 5 years from a societal perspective.

Methods: The CP, a New Paradigm 1 (NP1), and a New Paradigm 2 (NP2) were evaluated in a Markov model. The NP1 model simplifies monitoring and laboratory test requirements in the diagnosis and treatment phases. The NP2 model also eliminates the primary care referral requirement.

Results: Treatment process time for non-cirrhotic patients was 48, 43, and 25 weeks in the CP, NP1, and NP2, respectively, and in cirrhotic patients was 49, 46, and 37 weeks. Under the CP, 19% of patients/year would be lost to follow-up, which decreases by 11% in NP1 and 100% in NP2. Compared with the CP, implementation of NP1 at 5 years would reduce compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths by 12.6%, 12.4%, 8.1%, and 8.8%, respectively; these cases would be reduced by 94.0%, 93.8%, 61.0%, and 58.4% in NP2. Total 5-year costs with the CP, NP1, and NP2 are estimated at 135.6€ million, 110.5€ million, and 80.5€ million, respectively.

Conclusions: Simplification of HCV diagnosis and monitoring requirements would allow Italy to move closer to international guidelines with significant health benefits and economic gains.

References

Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B . Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Clinicoecon Outcomes Res. 2016; 8:15-21. PMC: 4706121. DOI: 10.2147/CEOR.S93641. View

Buggisch P, Wursthorn K, Stoehr A, Atanasov P, Supiot R, Lee J . Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One. 2019; 14(4):e0214795. PMC: 6448908. DOI: 10.1371/journal.pone.0214795. View

Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen K . Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014; 9(7):e103345. PMC: 4113410. DOI: 10.1371/journal.pone.0103345. View

DiBonaventura M, Yuan Y, Lescrauwaet B, LItalien G, Liu G, Kamae I . Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS One. 2014; 9(1):e86070. PMC: 3897615. DOI: 10.1371/journal.pone.0086070. View

Ruggeri M, Romano F, Basile M, Coretti S, Rolli F, Drago C . Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Appl Health Econ Health Policy. 2018; 16(5):711-722. DOI: 10.1007/s40258-018-0410-x. View

Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi M, Pasulo L . Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019; 71(6):1106-1115. DOI: 10.1016/j.jhep.2019.07.020. View

Thein H, Yi Q, Dore G, Krahn M . Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48(2):418-31. DOI: 10.1002/hep.22375. View

Ruggeri M, Coretti S, Romano F, Kondili L, Vella S, Cicchetti A . Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. Value Health. 2018; 21(7):783-791. DOI: 10.1016/j.jval.2017.10.021. View

Thein H, Yi Q, Dore G, Krahn M . Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22(15):1979-91. DOI: 10.1097/QAD.0b013e32830e6d51. View

10.

. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3):161-176. DOI: 10.1016/S2468-1253(16)30181-9. View

11.

Chen Q, Ayer T, Bethea E, Kanwal F, Wang X, Roberts M . Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019; 9(6):e026726. PMC: 6576109. DOI: 10.1136/bmjopen-2018-026726. View

12.

Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V . SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS One. 2019; 14(5):e0215783. PMC: 6519817. DOI: 10.1371/journal.pone.0215783. View

13.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

14.

Moussalli J, Delaquaize H, Boubilley D, Lhomme J, Merleau Ponty J, Sabot D . Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010; 2010. PMC: 2926583. DOI: 10.1155/2010/261472. View

15.

Gordon S, Lee J, Smith N, Dieterich D . Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res. 2019; 20(3):251-257. DOI: 10.1080/14737167.2019.1629291. View

16.

Gardini I, Bartoli M, Conforti M, Mennini F, Marcellusi A . Estimation of the number of HCV-positive patients in Italy. PLoS One. 2019; 14(10):e0223668. PMC: 6822946. DOI: 10.1371/journal.pone.0223668. View